CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Intermittenly scanned continuous glucose monitoring +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05918484
NCT05918484N/ACompleted

Usefulness of Intermittently Scanned Continuous Glucose Monitoring in the Diagnosis of Maturity-onset Diabetes of the Young (MODY) Patients

Castilla-La Mancha Health Service·observational·Posted Jun 26, 2023·Updated Feb 10, 2025

In Brief

An observational study evaluating Intermittenly scanned continuous glucose monitoring and MODY genetic diagnostic test for Type 1 Diabetes and MODY. Completed, enrolled 500 participants across 9 sites.

Detailed Summary

Observational study about usefulness of intermittently scanned continuous glucose monitoring (isCGM) in the diagnosis of maturity-onset of the young (MODY) patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJun 26, 2023
Enrollment StartJul 1, 2023
Primary CompletionJan 1, 2025
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.0 years ago

Interventions

Intermittenly scanned continuous glucose monitoringdevice

Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria: * Time in range 70-180 mg/L \>70% * Glycemic management index \<7% * Coefficient of variation \<36%

MODY genetic diagnostic testother

Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion: * diagnosis before 35 years of age * first-degree family history of diabetes. * negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8) * preserved pancreatic beta cell function defined as C-peptide \> 0.2 ng/mL in the presence of plasma glycemia \>140 mg/dL). Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test.